title: Recombinant human granulocyte-colony stimulating factor: in vitro and in vivo effects on myelopoiesis.
abstract: The results presented in this paper demonstrate that recombinant human granulocyte-colony stimulating factor (rhG-CSF) is a potent myelopoietic growth and differentiation factor in vivo. RhG-CSF was able to shorten the time period of neutrophil recovery in both cyclophosphamide (CY)-induced myelosuppression and following bone marrow transplantation (BMT) in primates. Its ability to significantly shorten the period of chemotherapy-induced bone marrow hypoplasia may allow clinicians to increase the frequency or dosage of chemotherapeutic agents. In addition, the increase in absolute numbers of functionally active neutrophils may have a profound effect on the rate and severity of neutropenia-related sepsis. Furthermore, the activities reported here indicate a potential role for rhG-CSF in the treatment of patients with myelodysplastic syndrome, congenital agranulocytosis, radiation-induced myelosuppression, and after bone marrow transplantation.
authors.affiliation: Laboratory of Cytokine Biology, Memorial Sloan-Kettering Cancer Center, New York, NY 10021.
authors.forename: K
authors.initials: K
authors.lastname: Welte
authors.forename: M A
authors.initials: MA
authors.lastname: Bonilla
authors.forename: J L
authors.initials: JL
authors.lastname: Gabrilove
authors.forename: A P
authors.initials: AP
authors.lastname: Gillio
authors.forename: G K
authors.initials: GK
authors.lastname: Potter
authors.forename: M A
authors.initials: MA
authors.lastname: Moore
authors.forename: R J
authors.initials: RJ
authors.lastname: O'Reilly
authors.forename: T C
authors.initials: TC
authors.lastname: Boone
authors.forename: L M
authors.initials: LM
authors.lastname: Souza
mesh_terms: D000818:Animals; D001853:Bone Marrow / Q000187:drug effects; D001854:Bone Marrow Cells; D001855:Bone Marrow Diseases / Q000188:drug therapy; D016026:Bone Marrow Transplantation; D002454:Cell Differentiation / Q000187:drug effects; D003115:Colony-Stimulating Factors / Q000494:pharmacology* / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000494:pharmacology; D006410:Hematopoiesis / Q000187:drug effects*; D006411:Hematopoiesis, Extramedullary / Q000187:drug effects; D006412:Hematopoietic Stem Cells / Q000187:drug effects; D006801:Humans; D007942:Leukemia, Experimental / Q000473:pathology; D008252:Macaca fascicularis; D051379:Mice; D009504:Neutrophils / Q000166:cytology; D011994:Recombinant Proteins / Q000494:pharmacology / Q000627:therapeutic use; D014182:Transplantation, Autologous; D014407:Tumor Cells, Cultured / Q000187:drug effects
chemical_list: D003115:Colony-Stimulating Factors; D011994:Recombinant Proteins; D003520:Cyclophosphamide